SOD1 and amyotrophic lateral sclerosis: It therefore must be acknowledged that any therapeutic efficacy identified for CuII(atsm) in the treatment of ALS may also feasibly occur via pathways that are either in conjunction with, or entirely independent of, alterations to SOD1 biochemistry.